Theriva biologics reports first quarter 2023 operational highlights and financial results

– continued to enroll patients in virage, the phase 2b clinical trial of systemically administered vcn-01 in combination with chemotherapy for pancreatic ductal adenocarcinoma –

TOVX Ratings Summary

TOVX Quant Ranking